Fulvestrant

• Endocrine therapy plus CDK 4/6 inhibition in first- or second-line for hormone receptor positive advanced breast cancer - the SONIA study Ended
  2024-516204-42-00 Phase III 1 country BOOG Study Center B.V.
• PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended
  2024-510704-37-00 Phase III 1 country Unicancer
• A Study of abemaciclib Combined with Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Ended
  2023-506781-30-00 Phase III 5 countries Eli Lilly & Co.
• (VELA) Study of BLU-222 in Advanced Solid Tumors Ended
  2022-502528-29-00 Phase I (FiH) 4 countries Blueprint Medicines Corp.
• Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) me… Ended
  2022-502372-22-01 Phase II 1 country Unicancer
• Milademetan and fulvestrant in GATA3-mutant, ER-positive, HER2-negative advanced or metastatic breast cancer patients (DEMETER) Ended
  2022-502360-21-00 Phase II 1 country Institut Curie
• A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced HR Positive and HER2-Negative BC Ended
  2023-503903-27-00 Phase II 2 countries Carrick Therapeutics Limited
• DESTINY-Breast08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other thera… Ended
  2023-505690-33-00 Phase I (Other) 1 country Astrazeneca AB
• Tucatinib and trastuzumab in solid tumors with HER2 alterations Ended
  2024-511481-37-00 Phase II 3 countries Seagen Inc.
• A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a … Ended
  2023-509591-42-00 Phase II 3 countries Medica Scientia Innovation Research S.L.
• Study to evaluate the effect of metformin in the prevention of hyperglycemia in HR[+]/HER2[–] PIK3CA-mutated advanced breast cancer patients… Ended
  2024-511295-33-00 Phase II 1 country Medica Scientia Innovation Research S.L.
• Study to evaluate the safety and tolerability of ZW25 in combination with palbociclib plus fulvestrant Ended
  2023-508135-30-00 Phase II 1 country Jazz Pharmaceuticals Ireland Limited
• Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3C… Ended
  2023-509167-24-00 Phase II 2 countries Novartis Pharma AG
• Clinical trial to compare the efficacy and tolerability of fulvestrant (FaslodexTM) 500mg with placebo versus fulvestrant (FaslodexTM) 500mg… Ended
  2024-516132-10-00 Phase II 2 countries Fundacion Grupo Espanol De Investigacion En Cancer De Mama
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan… Ended
  2023-506487-13-00 Phase III 14 countries Pfizer Inc.

Showing 49–63 of 63 trials